Revenue Growth Acceleration
Total revenue grew 14.3% YoY to $1.14B in Q1 FY2026 from $998.4M in the prior-year period, reflecting robust demand across IDEXX's diagnostics and veterinary software segments.
IDEXX LABORATORIES INC /DE is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: IDEXX Laboratories delivered strong Q1 FY2026 results with revenue of $1.14B (+14.3% YoY) and net income of $278.4M (+14.7% YoY), driven by expanding gross margins and solid operating cash flow generation.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue grew 14.3% YoY to $1.14B in Q1 FY2026 from $998.4M in the prior-year period, reflecting robust demand across IDEXX's diagnostics and veterinary software segments.
Gross margin improved approximately 91 basis points YoY to 63.35% from 62.44%, indicating favorable product mix and operational leverage as revenue growth outpaced cost of revenue growth of 11.5%.
Operating income rose 14.5% YoY to $362.6M, with operating margin holding nearly flat at 31.78% vs. 31.70% prior year, demonstrating cost discipline even as R&D spending increased 11.4% YoY to $65.8M.
Revenue
$1.14B
++14.26% YoY
EPS (Basic)
$3.50
++17.45% YoY
Gross Margin
63.4%
++0.92% YoY
Operating Income
$362.59M
++14.55% YoY
Add IDXX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.